Bavarian Nordic A/S (BAVA.CO)

DKK 198.95

(2.82%)

Total Debt Summary of Bavarian Nordic A/S

  • Bavarian Nordic A/S's latest annual total debt in 2023 was 145.3 Million DKK , down -91.74% from previous year.
  • Bavarian Nordic A/S's latest quarterly total debt in 2024 Q2 was 124.61 Million DKK , down -6.72% from previous quarter.
  • Bavarian Nordic A/S reported annual total debt of 1.75 Billion DKK in 2022, up 55.34% from previous year.
  • Bavarian Nordic A/S reported annual total debt of 1.13 Billion DKK in 2021, up 140.94% from previous year.
  • Bavarian Nordic A/S reported quarterly total debt of 133.59 Million DKK for 2024 Q1, down -8.06% from previous quarter.
  • Bavarian Nordic A/S reported quarterly total debt of 145.3 Million DKK for 2023 Q4, up 36.96% from previous quarter.

Annual Total Debt Chart of Bavarian Nordic A/S (2023 - 2001)

Historical Annual Total Debt of Bavarian Nordic A/S (2023 - 2001)

Year Total Debt Total Debt Growth
2023 145.3 Million DKK -91.74%
2022 1.75 Billion DKK 55.34%
2021 1.13 Billion DKK 140.94%
2020 470.06 Million DKK -74.34%
2019 1.83 Billion DKK 183.37%
2018 646.49 Million DKK 60.85%
2017 401.91 Million DKK 1161.89%
2016 31.85 Million DKK -4.33%
2015 33.29 Million DKK -5.36%
2014 35.17 Million DKK -56.2%
2013 80.31 Million DKK -10.14%
2012 89.37 Million DKK -9.86%
2011 99.15 Million DKK -7.16%
2010 106.79 Million DKK 0.0%
2009 - DKK 0.0%
2008 - DKK -100.0%
2007 149.83 Million DKK -25.35%
2006 200.71 Million DKK -21.81%
2005 256.71 Million DKK 0.0%
2004 - DKK -100.0%
2003 645 Thousand DKK 3.53%
2002 623 Thousand DKK 2495.83%
2001 24 Thousand DKK 0.0%

Peer Total Debt Comparison of Bavarian Nordic A/S

Name Total Debt Total Debt Difference
ALK-Abelló A/S 765 Million DKK 81.006%
Genmab A/S 770 Million DKK 81.13%
Gubra A/S 71.43 Million DKK -103.404%
Novo Nordisk A/S 27 Billion DKK 99.462%
Orphazyme A/S - DKK -Infinity%
Pharma Equity Group A/S 30.22 Million DKK -380.798%
Zealand Pharma A/S 200.27 Million DKK 27.449%